OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
16
Results
Show all
Save search
Copy query
Show results for
Unknown
(16)
Publication Date
Release Date
2025
(5)
2024
(3)
2023
(3)
2022
(3)
2021
(2)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Ultrasmall Manganese Oxide Nanoparticles as Contrast Agents for T<sub>1</sub>‑T<sub>2</sub> Dual-Modal Magnetic Resonance Imaging.
Not available
S-EPMC12444676
|
biostudies-literature
Cite
Antibacterial efficacy of low-dosage silver nanoparticle-sodium alginate-chitosan nanocomposite films against pure and clinical acne strains.
Not available
S-EPMC11492429
|
biostudies-literature
Cite
Tumour microbiomes and Fusobacterium genomics in Vietnamese colorectal cancer patients.
Not available
S-EPMC9616903
|
biostudies-literature
Cite
Detection of Immunity Gap before Measles Outbreak, Ho Chi Minh City, Vietnam, 2024.
Not available
S-EPMC12483019
|
biostudies-literature
Cite
Global Burden of Cardiovascular Diseases and Risks, 1990-2022.
Not available
S-EPMC7615984
|
biostudies-literature
Cite
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study.
Not available
S-EPMC11578795
|
biostudies-literature
Cite
Sex Differences in Long COVID.
Not available
S-EPMC11755195
|
biostudies-literature
Cite
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607
|
biostudies-literature
Cite
Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.
Not available
S-EPMC12464792
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets